Global biotechnology company Bioverativ Inc., announced that clinical data from its leading extended half-life therapies Alprolix and Eloctate indicates that the medications improve joint health, bleeding, and the quality of life of hemophilia patients.
Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] and Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein] are synthetic coagulation factors VIII and IX, for hemophilia A and B, respectively.
The data showed that hemophilia patients who were given Eloctate and Alprolix exhibited improved joint health scores and joint annualized bleed rates.
Meanwhile, Bioverativ Canada Inc. reported that it has received notices of compliance from Health Canada approving the transfer of marketing licenses for Eloctate and Alprolix from Biogen Canada Inc. to Bioverativ Canada Inc., following Bioverativ’s separation from Biogen.
Eloctate and Alprolix are the first extended half-life therapies available to the estimated 4,000 Canadians living with hemophilia A and B, according to Bioverative Canada. The rare genetic disorder is caused by the absence of or defective clotting factors which lead to impaired blood clotting.
Hemophilia A occurs in about one in 5,000 male births annually, and more rarely in females. Hemophilia B occurs in about one in 25,000 male births annually, and more rarely in females. The World Federation of Hemophilia estimates that approximately 180,000 people are currently diagnosed with hemophilia A and B worldwide.
Bioverativ was created as a spin-off from Biogen’s hemophilia business and is an independent biotechnology company focused on the discovery, development, and commercialization of innovative therapies for hemophilia and other rare blood disorders.
Following the spin-off, effective February 1, 2017, Biogen was the marketing authorization holder of Eloctate and Alproxil in Canada until Health Canada approved the transfer of the marketing licenses to Bioverativ Canada Inc.
Dr. Tim Harris, executive vice-president of research and development at Bioverative Inc., said the company will present the clinical data on Eloctate and Alproxil this month at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress, taking place in Berlin.
“Our data at ISTH will also highlight our work to develop a pipeline of novel therapies for hemophilia, including several presentations on BIVV001, our potential next-generation factor VIII therapy designed to extend protection from bleeds with prophylaxis dosing of once weekly or longer,” he said.